A newly identified role for superoxide in inflammatory pain

Zhi Qiang Wang, Frank Porreca, Salvatore Cuzzocrea, Karen Galen, Richard Lightfoot, Emanuela Masini, Carolina Muscoli, Vincenzo Mollace, Michael Ndengele, Harry Ischiropoulos, Daniela Salvemini

Research output: Contribution to journalArticle

276 Citations (Scopus)

Abstract

Novel classes of pain-relieving molecules are needed to fill the void between nonsteroidal anti-inflammatory agents and narcotics. Our studies have identified superoxide as a novel mediator of hyperalgesia (clinically defined as an augmented sensitivity to painful stimuli) and have exposed potential pathways through which this radical modulates the hyperalgesic response. The role of superoxide in pain was elucidated using a superoxide dismutase mimetic, M40403 [a manganese(II) complex with a bis(cyclo-hexylpyridine-substituted) macrocyclic ligand]. Intraplantar injection of carrageenan in rats led to time-dependent development of peripheral inflammation [measured parameters of inflammation included paw edema, cytokine release in the paw exudates, nitrotyrosine formation (a marker of peroxynitrite formation and oxidative stress), and poly-ADP-ribose-polymerase activation (the nuclear enzyme activated by superoxide/peroxynitrite)] and hyperalgesia. M40403 blocked all measured parameters of inflammation and hyperalgesia. Furthermore, when given therapeutically (2 h after the induction of hyperalgesia) either by intravenous or intrathecal administration, M40403 but not its inactive congener M40404 inhibited hyperalgesia with a rapid onset of action. Our results also show that, at the level of the spinal cord and time of peak hyperalgesia, endogenous manganese superoxide dismutase was nitrated and subsequently deactivated, losing its capacity to remove superoxide. The antihyperalgesic effects of M40403 were not reversed by naloxone excluding the potential involvement of an opiate pathway. Collectively, these studies have unraveled a critical role for superoxide in the nociceptive signaling cascade both peripherally and centrally. The discovery of this pathway opens a new therapeutic strategy for the development of novel nonnarcotic antihyperalgesic agents.

Original languageEnglish (US)
Pages (from-to)869-878
Number of pages10
JournalJournal of Pharmacology and Experimental Therapeutics
Volume309
Issue number3
DOIs
StatePublished - Jun 2004

Fingerprint

Hyperalgesia
Superoxides
Pain
Peroxynitrous Acid
Inflammation
Superoxide Dismutase
Opiate Alkaloids
Enzyme Activation
Poly(ADP-ribose) Polymerases
Carrageenan
Narcotics
Non-Steroidal Anti-Inflammatory Agents
Exudates and Transudates
Manganese
Naloxone
Edema
Spinal Cord
Oxidative Stress
Cytokines
Ligands

ASJC Scopus subject areas

  • Pharmacology

Cite this

Wang, Z. Q., Porreca, F., Cuzzocrea, S., Galen, K., Lightfoot, R., Masini, E., ... Salvemini, D. (2004). A newly identified role for superoxide in inflammatory pain. Journal of Pharmacology and Experimental Therapeutics, 309(3), 869-878. https://doi.org/10.1124/jpet.103.064154

A newly identified role for superoxide in inflammatory pain. / Wang, Zhi Qiang; Porreca, Frank; Cuzzocrea, Salvatore; Galen, Karen; Lightfoot, Richard; Masini, Emanuela; Muscoli, Carolina; Mollace, Vincenzo; Ndengele, Michael; Ischiropoulos, Harry; Salvemini, Daniela.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 309, No. 3, 06.2004, p. 869-878.

Research output: Contribution to journalArticle

Wang, ZQ, Porreca, F, Cuzzocrea, S, Galen, K, Lightfoot, R, Masini, E, Muscoli, C, Mollace, V, Ndengele, M, Ischiropoulos, H & Salvemini, D 2004, 'A newly identified role for superoxide in inflammatory pain', Journal of Pharmacology and Experimental Therapeutics, vol. 309, no. 3, pp. 869-878. https://doi.org/10.1124/jpet.103.064154
Wang, Zhi Qiang ; Porreca, Frank ; Cuzzocrea, Salvatore ; Galen, Karen ; Lightfoot, Richard ; Masini, Emanuela ; Muscoli, Carolina ; Mollace, Vincenzo ; Ndengele, Michael ; Ischiropoulos, Harry ; Salvemini, Daniela. / A newly identified role for superoxide in inflammatory pain. In: Journal of Pharmacology and Experimental Therapeutics. 2004 ; Vol. 309, No. 3. pp. 869-878.
@article{fd080708c53e4064ae03f1a0c688e049,
title = "A newly identified role for superoxide in inflammatory pain",
abstract = "Novel classes of pain-relieving molecules are needed to fill the void between nonsteroidal anti-inflammatory agents and narcotics. Our studies have identified superoxide as a novel mediator of hyperalgesia (clinically defined as an augmented sensitivity to painful stimuli) and have exposed potential pathways through which this radical modulates the hyperalgesic response. The role of superoxide in pain was elucidated using a superoxide dismutase mimetic, M40403 [a manganese(II) complex with a bis(cyclo-hexylpyridine-substituted) macrocyclic ligand]. Intraplantar injection of carrageenan in rats led to time-dependent development of peripheral inflammation [measured parameters of inflammation included paw edema, cytokine release in the paw exudates, nitrotyrosine formation (a marker of peroxynitrite formation and oxidative stress), and poly-ADP-ribose-polymerase activation (the nuclear enzyme activated by superoxide/peroxynitrite)] and hyperalgesia. M40403 blocked all measured parameters of inflammation and hyperalgesia. Furthermore, when given therapeutically (2 h after the induction of hyperalgesia) either by intravenous or intrathecal administration, M40403 but not its inactive congener M40404 inhibited hyperalgesia with a rapid onset of action. Our results also show that, at the level of the spinal cord and time of peak hyperalgesia, endogenous manganese superoxide dismutase was nitrated and subsequently deactivated, losing its capacity to remove superoxide. The antihyperalgesic effects of M40403 were not reversed by naloxone excluding the potential involvement of an opiate pathway. Collectively, these studies have unraveled a critical role for superoxide in the nociceptive signaling cascade both peripherally and centrally. The discovery of this pathway opens a new therapeutic strategy for the development of novel nonnarcotic antihyperalgesic agents.",
author = "Wang, {Zhi Qiang} and Frank Porreca and Salvatore Cuzzocrea and Karen Galen and Richard Lightfoot and Emanuela Masini and Carolina Muscoli and Vincenzo Mollace and Michael Ndengele and Harry Ischiropoulos and Daniela Salvemini",
year = "2004",
month = "6",
doi = "10.1124/jpet.103.064154",
language = "English (US)",
volume = "309",
pages = "869--878",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "3",

}

TY - JOUR

T1 - A newly identified role for superoxide in inflammatory pain

AU - Wang, Zhi Qiang

AU - Porreca, Frank

AU - Cuzzocrea, Salvatore

AU - Galen, Karen

AU - Lightfoot, Richard

AU - Masini, Emanuela

AU - Muscoli, Carolina

AU - Mollace, Vincenzo

AU - Ndengele, Michael

AU - Ischiropoulos, Harry

AU - Salvemini, Daniela

PY - 2004/6

Y1 - 2004/6

N2 - Novel classes of pain-relieving molecules are needed to fill the void between nonsteroidal anti-inflammatory agents and narcotics. Our studies have identified superoxide as a novel mediator of hyperalgesia (clinically defined as an augmented sensitivity to painful stimuli) and have exposed potential pathways through which this radical modulates the hyperalgesic response. The role of superoxide in pain was elucidated using a superoxide dismutase mimetic, M40403 [a manganese(II) complex with a bis(cyclo-hexylpyridine-substituted) macrocyclic ligand]. Intraplantar injection of carrageenan in rats led to time-dependent development of peripheral inflammation [measured parameters of inflammation included paw edema, cytokine release in the paw exudates, nitrotyrosine formation (a marker of peroxynitrite formation and oxidative stress), and poly-ADP-ribose-polymerase activation (the nuclear enzyme activated by superoxide/peroxynitrite)] and hyperalgesia. M40403 blocked all measured parameters of inflammation and hyperalgesia. Furthermore, when given therapeutically (2 h after the induction of hyperalgesia) either by intravenous or intrathecal administration, M40403 but not its inactive congener M40404 inhibited hyperalgesia with a rapid onset of action. Our results also show that, at the level of the spinal cord and time of peak hyperalgesia, endogenous manganese superoxide dismutase was nitrated and subsequently deactivated, losing its capacity to remove superoxide. The antihyperalgesic effects of M40403 were not reversed by naloxone excluding the potential involvement of an opiate pathway. Collectively, these studies have unraveled a critical role for superoxide in the nociceptive signaling cascade both peripherally and centrally. The discovery of this pathway opens a new therapeutic strategy for the development of novel nonnarcotic antihyperalgesic agents.

AB - Novel classes of pain-relieving molecules are needed to fill the void between nonsteroidal anti-inflammatory agents and narcotics. Our studies have identified superoxide as a novel mediator of hyperalgesia (clinically defined as an augmented sensitivity to painful stimuli) and have exposed potential pathways through which this radical modulates the hyperalgesic response. The role of superoxide in pain was elucidated using a superoxide dismutase mimetic, M40403 [a manganese(II) complex with a bis(cyclo-hexylpyridine-substituted) macrocyclic ligand]. Intraplantar injection of carrageenan in rats led to time-dependent development of peripheral inflammation [measured parameters of inflammation included paw edema, cytokine release in the paw exudates, nitrotyrosine formation (a marker of peroxynitrite formation and oxidative stress), and poly-ADP-ribose-polymerase activation (the nuclear enzyme activated by superoxide/peroxynitrite)] and hyperalgesia. M40403 blocked all measured parameters of inflammation and hyperalgesia. Furthermore, when given therapeutically (2 h after the induction of hyperalgesia) either by intravenous or intrathecal administration, M40403 but not its inactive congener M40404 inhibited hyperalgesia with a rapid onset of action. Our results also show that, at the level of the spinal cord and time of peak hyperalgesia, endogenous manganese superoxide dismutase was nitrated and subsequently deactivated, losing its capacity to remove superoxide. The antihyperalgesic effects of M40403 were not reversed by naloxone excluding the potential involvement of an opiate pathway. Collectively, these studies have unraveled a critical role for superoxide in the nociceptive signaling cascade both peripherally and centrally. The discovery of this pathway opens a new therapeutic strategy for the development of novel nonnarcotic antihyperalgesic agents.

UR - http://www.scopus.com/inward/record.url?scp=2442648975&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2442648975&partnerID=8YFLogxK

U2 - 10.1124/jpet.103.064154

DO - 10.1124/jpet.103.064154

M3 - Article

C2 - 14988418

AN - SCOPUS:2442648975

VL - 309

SP - 869

EP - 878

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 3

ER -